Neuromyelitis optica spectrum disorder presents unique neuroimaging challenges during acute spinal attacks. Clinicians frequently encounter longitudinally extensive transverse myelitis, but distinguishing it from mimickers remains difficult. Identifying validated NMOSD spinal MRI signs allows rapid therapeutic intervention before irreversible neurological deficits occur. A retrospective cohort study evaluates established and novel neuroimaging markers to enhance diagnostic precision.

Evaluating Established and Novel NMOSD Spinal MRI Signs

Acute myelitis represents one of the most debilitating manifestations of aquaporin-4 immunoglobulin G-seropositive neuromyelitis optica spectrum disorder. Although longitudinally extensive transverse myelitis remains the diagnostic hallmark, non-inflammatory cord disorders frequently mimic its linear longitudinal extent. Consequently, investigators conducted a retrospective study at a major academic hospital to assess specific neuroimaging features across disease phases. The analysis reviewed three hundred thirty-one magnetic resonance scans from two hundred seventeen seropositive patients. In addition, researchers analyzed seventy-two control scans from individuals with alternative myelopathies, including spinal cord infarction and idiopathic myelitis. Among patients experiencing their first-ever clinical myelitis event, longitudinally extensive cord lesions occurred in nearly eighty-nine percent. However, standard lesion length alone cannot reliably exclude vascular or infectious causes. Therefore, evaluating specific parenchymal and contrast configurations provides crucial diagnostic refinement. Clinicians must recognize characteristic imaging signatures during the earliest acute stage to prevent catastrophic disability. Early identification prevents catastrophic delays in deploying targeted immunosuppressive rescue therapies like high-dose corticosteroids or plasma exchange.

Diagnostic Performance of the Double-Contoured LETM Sign

The study highlights the novel double-contoured longitudinally extensive transverse myelitis sign as a distinctive neuroimaging biomarker. This sign features layered central and peripheral signal alterations within the swollen spinal cord on axial and sagittal T2 sequences. During first-ever acute myelitis attacks, this novel marker demonstrated a sensitivity of 47.2% and an impressive specificity of 98.6%. Therefore, observing this specific configuration offers robust evidence favoring aquaporin-4 autoimmunity over vascular ischemia. Nevertheless, the sensitivity dropped to approximately twenty percent when researchers evaluated recurrent myelitis episodes alongside initial attacks. Prior tissue injury, localized gliosis, and chronic structural remodeling likely obscure subtle layered patterns during repeat exacerbations. Furthermore, combining this novel sign with other established markers increased specificity beyond ninety-nine percent, although overall diagnostic sensitivity dropped toward thirty percent. Radiologists should deliberately scrutinize baseline T2-weighted acquisitions for this double-contoured morphology. Recognizing this pattern during acute presentation empowers clinicians to initiate definitive immunotherapy while awaiting confirmatory serology results.

Utility of Bright Spotty Lesions in Acute Myelitis

Bright spotty lesions represent another indispensable diagnostic signature on spinal magnetic resonance imaging. Radiologists define these lesions as focal, hyperintense patches on T2-weighted scans that match or exceed surrounding cerebrospinal fluid intensity without central cord cavitation. In first-time acute myelitis attacks, bright spotty lesions achieved a diagnostic sensitivity of 64.0% alongside an extraordinary specificity of 98.6%. Consequently, their presence strongly steers the differential diagnosis toward an aquaporin-4 antibody-mediated astrocytopathy. When evaluators analyzed first-time and recurrent episodes collectively, the prevalence of bright spotty lesions remained relatively substantial at 56.5%. Because spinal cord ischemia and multiple sclerosis seldom produce marked hyperintensity of this magnitude, these lesions serve as highly reliable differentiators. Pathologically, these focal spots correlate with extensive tissue necrosis, blood-brain barrier breakdown, and profound astrocyte loss driven by complement activation. Clinicians practicing in emergency neurology settings should actively search for bright spotty lesions whenever encountering longitudinally extensive cord inflammation.

Significance of Sagittal Ring Enhancement Patterns

Post-contrast T1-weighted sequences provide vital complementary data when evaluating suspected inflammatory myelopathies. Sagittal ring enhancement, characterized by rim-like peripheral enhancement surrounding non-enhancing necrotic cord tissue, demonstrates remarkable diagnostic value. In the primary first-ever myelitis cohort, this pattern exhibited a sensitivity of 60.0% and a specificity of 96.4%. Thus, ring enhancement effectively distinguishes autoimmune astrocytopathy from diffuse patchy enhancement commonly seen in post-infectious demyelination. When evaluating recurrent and initial attacks together, the overall prevalence of sagittal ring enhancement declined to 44.1%. This temporal variation emphasizes that active microvascular disruption and severe localized inflammation peak during early presentations. In contrast, spinal cord infarctions typically lack rim-enhancing borders during hyperacute stages. Similarly, short-segment plaques in multiple sclerosis rarely form extensive sagittal rings. Therefore, clinicians must routinely include contrast-enhanced acquisitions in spinal protocols. Integrating contrast dynamics with unenhanced T2 markers establishes an accurate neuroimaging profile for complex myelopathic presentations.

Longitudinal Evolution and Clinical Implications in Practice

Spinal cord imaging abnormalities undergo profound structural transformations following the acute phase of attack. During clinical remission, complete radiologic resolution occurred in only 12.4% of evaluated follow-up scans. In stark contrast, permanent spinal cord atrophy developed in 56.6% of patients, underscoring the destructive nature of antibody-mediated attacks. Consequently, acute tissue preservation through prompt immunosuppressive intervention represents an urgent priority. While combining bright spotty lesions, double-contoured configurations, and ring enhancement provides near-absolute specificity, the resulting lower sensitivity limits sole reliance on combined panels. Clinicians should interpret individual signs within the appropriate clinical context rather than demanding every feature appear simultaneously. Notably, the study comparison group contained numerous non-inflammatory myelopathies, highlighting the need for further validation in diverse demyelinating cohorts. Nevertheless, recognizing these distinctive signs enables rapid initiation of apheresis or targeted biologics. In resource-limited or emergency settings where antibody assays require days to return, these imaging markers guide critical life-saving decisions.

Frequently Asked Questions

What is the novel double-contoured LETM sign in NMOSD?

The double-contoured longitudinally extensive transverse myelitis sign is a novel neuroimaging pattern observed on spinal cord magnetic resonance imaging. It appears as layered, distinct signal intensities within swollen spinal cord tissue during acute attacks. Demonstrating a specificity of 98.6% in first-ever myelitis episodes, this sign provides clinicians with a powerful diagnostic marker. It reliably differentiates aquaporin-4-positive neuromyelitis optica spectrum disorder from acute spinal cord infarction and non-inflammatory myelopathies.

How do bright spotty lesions differentiate NMOSD from multiple sclerosis?

Bright spotty lesions appear as focal, marked hyperintensities on T2-weighted spinal imaging with signal intensity matching or exceeding surrounding cerebrospinal fluid. While multiple sclerosis typically produces discrete, peripheral, short-segment demyelinating plaques, bright spotty lesions reflect extensive necrosis and astrocyte destruction characteristic of neuromyelitis optica spectrum disorder. Their high specificity of 98.6% makes them extraordinarily useful for excluding multiple sclerosis and guiding appropriate antibody-depleting or complement-inhibiting therapies.

Why does the sensitivity of these spinal MRI signs decrease in recurrent myelitis?

The sensitivity of specific neuroimaging signs decreases in recurrent myelitis because chronic architectural changes alter tissue signal characteristics. Repeated inflammatory episodes often cause extensive cord atrophy, secondary cavitation, and diffuse gliosis. These structural alterations obscure discrete acute patterns like the double-contoured configuration or sagittal ring enhancement. Consequently, these imaging markers perform with maximum diagnostic sensitivity during first-ever acute presentations before cumulative parenchymal damage permanently remodels spinal tissue.

Disclaimer: This content is for informational and educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Sukhonpanich N et al. Diagnostic Utility of Novel and Established Spinal MRI Signs in AQP4-IgG-Seropositive NMOSD Myelitis. Neurology. 2026 Oct 13. doi: 10.1212/WNL.0000000000218507. PMID: 42766829.
2. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177-189.
3. Pekcevik Y, Mitchell CH, Mealy MA, et al. Differentiating neuromyelitis optica spectrum disorders from multiple sclerosis: value of bright spotty lesions on spinal cord MRI. Mult Scler. 2016;22(9):1265-1272.
4. Macken E, Flanagan EP. From Lesion Length to Lesion Pattern in Neuromyelitis Optica Spectrum Disorder Myelitis: Implications for Diagnostic Criteria. Neurology. 2026;107(7):e218600.